The PPARα agonist clofibrate has a beneficial cardiac effect on ischemia/reperfusion conditions by decreasing the inflammatory response that, in turn, decreases myocardial fibrosis, the MMP-2 expression, and apoptosis. Here, MMP2 is linked to Myocardial fibrosis.